St Marys House, St Marys Road, Leeds LS7 3JX, UK.
Correspondence: E-mail: Mahesh.Jayaram{at}leedsmh.nhs.uk
EDITED BY KIRIAKOS XENITIDIS and COLIN CAMPBELL
Valmaggia et al (2005) report an interesting randomised controlled trial evaluating cognitivebehavioural therapy (CBT) for refractory psychotic symptoms of schizophrenia resistant to atypical antipsychotic medication. They conclude that patients should not be excluded from psychological help on the grounds that they are too ill to benefit from therapy, and CBT for psychotic symptoms should be available in in-patient facilities.
We feel the conclusions drawn by the authors do not truly reflect their results. Valmaggia et al report that their primary hypothesis was that CBT would be more effective than supportive counselling in reducing auditory hallucinations and delusional beliefs. They used the Positive and Negative Syndrome Scale (PANSS) and Psychotic Symptoms Rating Scale (PSYRATS) to measure outcomes. The post-treatment score on the PANSS positive sub-scale of those receiving CBT was not significantly different from that of the control group. On the PSYRATS no significant effect was found on the delusions. Benefits of CBT were found on the auditory hallucinations scale for physical characteristics and cognitive interpretation but not for emotional characteristics. However, the benefits noticed were not sustained at follow-up. It would have been helpful if the authors had used an a priori definition of what constitutes a clinically meaningful improvement and provided the actual figures for the dichotomous outcome.
Also, if we look at the numbers needed to treat (NNT) calculations, the
authors have accurately reported the lack of statistical significance (PANSS
positive symptom scale, NNT=8, 95% CI 3; PSYRATS factor 2,
NNT=6, 95% CI 2
; delusion scale factor 1, NNT=4, 95% CI
2
; factor 2, NNT=12, 95% CI 3
). The only finding
with reasonable confidence intervals seems to be cognitive interpretation on
the auditory hallucination scale of the PSYRATS (NNT=3, 95% CI 213).
The authors also draw our attention to the fact that clozapine is effective in
32% of cases in producing a clinical improvement (NNT=5, 95% CI 47;
Wahlbeck et al, 1999).
They seem to suggest that the figures from the current study reveal the
effects of CBT to be similar to clozapine. However, it should be noted that
this figure reported by Wahlbeck et al is for global improvement,
whereas Valmaggia et al do not give any figures for global
improvement and hence in our opinion these results are not comparable. To
conclude from these results that CBT could induce a change in psychotic
symptoms seems to be overestimating the beneficial effects.
Patients with schizophrenia who are resistant to clozapine form one of the most difficult-to-treat groups. Jones et al (2004) concluded that trial-based data supporting the wide use of CBT for people with schizophrenia or other psychotic illnesses are far from conclusive. The randomised controlled study of Valmaggia et al evaluating interventions in this population is welcome.
REFERENCES
Jones, C., Cormac, I., Silveira da Mota Neto, J. I., et al (2004) Cognitive behaviour therapy for schizophrenia. Cochrane Database of Systematic Reviews, issue 4. Oxford: Update Software.
Valmaggia, L. R., Van der Gaag, M., Tarrier, N., et al
(2005) Cognitivebehavioural therapy for refractory
psychotic symptoms of schizophrenia resistant to atypical antipsychotic
medication: Randomised controlled trial. British Journal of
Psychiatry, 186, 324
330.
Wahlbeck, K., Cheine, M. & Essali, M. A. (1999) Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database of Systematic Reviews, issue 4. Oxford: Update Software.
HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Psychiatric Bulletin | Advances in Psychiatric Treatment | All RCPsych Journals |